News

Macrogen CSO Presents Vision for “$100 Genome, 100-Year Health” at Illumina Korea Press Conference
2025.06.18

 

SEOUL, South Korea – June 18, 2025 – Macrogen, a global leader in genomic analysis, announced that Dr. Seungbeen Lee, Chief Scientific Officer (CSO), presented at the Illumina Korea Press Conference held today at THE PLAZA Hotel in Seoul. His talk, titled "The $100 Genome and 100-Year Health: AI-Driven Digital Healthcare Revolution," highlighted Macrogen’s strategic transition into an AI- and data-driven precision medicine company.

 

During the session, Dr. Lee outlined the company’s vision for democratizing healthcare in the age of longevity by leveraging next-generation genomic technologies and artificial intelligence. "Macrogen is making a company-wide push to become a global precision medicine leader powered by AI and big data," said Dr. Lee. "We have long applied machine learning and AI internally, and we’re now expanding their use across all fronts—from research and data analysis to automation systems and customer-facing services."

 

This presentation comes on the heels of Macrogen’s recent declaration to transform into an AI and data-centric enterprise. On the company’s 28th anniversary, Chairman Jeong-sun Seo reaffirmed this vision, stating, "Founded on the belief that genomics should serve humanity, Macrogen is now moving forward to lead innovation in AI-powered precision medicine." In support of this transformation, Macrogen is not only incorporating AI into R&D and business operations but also investing in workforce development through AI certification programs for employees.

 

Dr. Lee also introduced new advancements in consumer-focused services, such as GenTok, Macrogen’s personalized healthcare solution. "By integrating generative AI, including technologies like ChatGPT, we’re enhancing user experience," he explained. "With GenTok, users receive easily understandable insights across 129 genetic traits, and they can ask GenTok AI follow-up questions to receive instant, relevant answers. This has received highly positive feedback from users."

 

A recognized expert in genomics, Dr. Lee earned his Ph.D. in Genome Sciences from the University of Washington. He currently heads Macrogen’s Technology Strategy Division and also serves as Director of Service Development and Analysis, overseeing clinical and direct-to-consumer testing platforms.

 

As South Korea’s top genomic analysis company, Macrogen continues to lead in national and global healthcare initiatives. In December 2024, the company was selected as the lead operator for Korea’s National Integrated Bio Big Data Project, and it is currently collaborating with Illumina Korea to build a cutting-edge national bio-data ecosystem.


TOP